Bottom Fish Stocks (between .10 and$10)

[zenvesting]

Stewart re: BIPH.ob:

No PR yet about BSX; but this was said during the BIPH investor CC:
"....Then, devices used in interventional medicine like the 48-inch long, stainless steel guidewires that are used to implant stents, these procedures are done under X-ray and the installing physicians are exposed to ionizing radiation, which is dangerous. They wear heavy lead aprons, which unfortunately, causes many of them to have back problems. So the question you might ask logically is, why don't they do these procedures under MRI where there is no ionizing radiation, and where you can see better soft tissue and better see this metal device that's being threaded through your vascular system?

The reason why is that, these guidewires both have a safety issue, they get hot and they blacken the image out. Now in the guide wire area, we've pretty much cracked the code on solving both of these problems and that not only is good for Biophan and our customers when they make MRI safe guidewires, but it could open up a whole new field of interventional medicine, which could be very beneficial to the MRI device manufacturers and to the physicians and to the patients. So these technologies have a fairly significant impact long-term on the healthcare industry. This, of course, will be very good for the Biophan shareholders.

This puts us in a very unique position in another interesting way. We are actively involved, mostly under confidentiality agreements, with many of the R&D and new business development people in most of the larger biomedical device companies. We have announced that we have a joint development agreement with Boston Scientific, which is going well and has moved into the second phase and is expanding into more product lines and we'll have information in the future with them on the status of that relationship.

I find it odd coinsidence that he brought up BSX and the expanded product lines, right after that very optomistic discussion of their work with stents and guidewires....I hope I am not reading into this too much; but man does that make me optomistic for the long-term.

This was also said:
"D. Eritt
Hello, Mr. Weiner. Congratulations on your company and the success you've had so far. I have one question about the next phase with Boston Scientific, any timeline for that?

M. Weiner
We've already moved into the next phase as I mentioned earlier; and the way these things work is that they and we have a shared interest in making certain products of theirs more competitive and more beneficial for patients. It is hard to predict exactly when during the R&D phase that you get to the point of comfort, where you want to make a decision in their case, to further extend their exclusive options or to commit a product to market.

Then, it's very hard for us to share with you where we really are because very often, these things are being done for competitive advantage purposes and you don't really want to signal to the competition too quickly, exactly what you're doing and when you'll get there. It may seem fairly vague with specifics, but you will be hearing more news about our relationship with them, and it is going forward."

As I read the SEC 8k rules, I would have thought that a change to the agreement would have needed to have been released in an 8k. I e-mailed the company with this question, citing the 8k disclosure rule changes from 3/04 and IR replied that they believe they are in compliance with those disclosure rules....so I guess we need to be patient?

The Cohen report was paid by the company, but from the www.Cohenresearch.com website, it looks like these reports get pretty wide distribution. It was probably a good move by the company to help build the audience of investors. I really believe the company is doing everything it can to improve market awareness before a big news item is released.

After a brief glance at LTHU.ob, I'm not seeing too much to get excited about? What's the story there?